Aclaris Therapeutics (ACRS) Return on Sales (2017 - 2026)

Aclaris Therapeutics' Return on Sales history runs 10 years deep, the most recent figure standing at 0.1% for Q1 2026.

• In Q1 2026, Return on Sales rose 1.0% year-over-year to 0.1%; the TTM figure through Mar 2026 stood at 0.09% (down 1.0% YoY), while the FY2025 annual figure was 0.09%, down 2.0% from the prior year.
• Return on Sales was 0.1% for Q1 2026 at Aclaris Therapeutics, up from 0.16% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q4 2023 to a low of 0.17% in Q2 2023.
• Historically, Return on Sales has averaged 0.08% across 5 years, with a median of 0.09% in 2025.
• Biggest YoY gain for Return on Sales was 13 bps in 2024; the steepest drop was 10 bps in 2024.
• A 5-year view of Return on Sales shows it stood at 0.04% in 2022, then soared by 97 bps to 0.0% in 2023, then slumped by 9917 bps to 0.11% in 2024, then slumped by 54 bps to 0.16% in 2025, then jumped by 36 bps to 0.1% in 2026.
• The last three Return on Sales figures came in at 0.1% (Q1 2026), 0.16% (Q4 2025), and 0.05% (Q3 2025), per Business Quant data.